News

Sirona Biochem Corp. announced that partner, Jiangsu Wanbang Biopharmaceuticals, has confirmed the Investigational New Drug (IND) submission to China’s Food and Drug Administration…
Read More...

Genmab A/S announced that it has entered into a research collaboration and exclusive license agreement with privately owned Immatics Biotechnologies GmbH (Immatics), to discover and…
Read More...

Pfenex Inc. announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3 clinical study of (V114), an investigational polyvalent conjugate…
Read More...

UL announced that together with Applied DNA Sciences Inc. they have joined forces to form a strategic partnership that will lay the foundation for a significant new development in…
Read More...

Otsuka Pharmaceutical and Visterra announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in…
Read More...

BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The…
Read More...

CURE Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences to acquire the non-pain assets of Therapix, subject to the completion of the related conditions.…
Read More...

AbbVie announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA) in untreated (treatment-naïve) diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin…
Read More...

Amphastar Pharmaceuticals announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals. To date, ANP has provided Active Pharmaceutical Ingredients and…
Read More...

Filament BioSolutions, a development-stage company focused on delivering innovative therapeutics for nutritional deficiencies, announced continued progress in the development of its…
Read More...

Catalent Pharma Solutions and Berkeley Lights announced Catalent Biologics will adopt BLI’s Beacon optofluidic platform to accelerate its cell line development workflow. The Beacon…
Read More...

Selexis SA announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs…
Read More...

SRI International announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis'…
Read More...

BioCryst Pharmaceuticals announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals following the BioCryst stockholders’ failure to approve…
Read More...

ProBioGen AG and Pionyr Immunotherapeutics announced a second service and license agreement to develop novel antibody therapeutics. Under the terms of the agreement, ProBioGen will…
Read More...

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced that its…
Read More...

BioIVT announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems…
Read More...

Teva Pharmaceutical Industries  announced the launch of a generic version of Uceris1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are…
Read More...

Herantis Pharma Plc announced the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson’s disease and potentially other neurodegenerative…
Read More...

Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of…
Read More...